Ideas

Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA TUG1 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 10/March/2019, 2.15 pm
Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA TUG1 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 10/March/2019, 2.15 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Probiotic-based therapy for autoimmune diabetes: Probiotic  Dulac ATP increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 10/March/2019, 1.47 pm
Probiotic-based therapy for autoimmune diabetes: Probiotic  Dulac ATP increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 10/March/2019, 1.47 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan…

read more

Molecular therapy for inflammation and arthritis:  Methylene blue(MB) (trade names: Urelene blue, Provayblue, Proveblue) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 10/March/2018, 1.29 pm
Molecular therapy for inflammation and arthritis:  Methylene blue(MB) (trade names: Urelene blue, Provayblue, Proveblue) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 10/March/2018, 1.29 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany shows that “Resolution of inflammation by…

read more

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA BLACAT1  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 10/March/2019, 1.17 pm
Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA BLACAT1  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 10/March/2019, 1.17 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School…

read more

Anti-infective Therapy:  Nutlin-3a inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 10/March/2019,  1.09 pm
Anti-infective Therapy:  Nutlin-3a inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 10/March/2019,  1.09 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins…

read more

Ribonucleic acid-based pain medication therapy:  LncRNA NEAT1 increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 10/March/2019, 12.45 pm
Ribonucleic acid-based pain medication therapy:  LncRNA NEAT1 increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 10/March/2019, 12.45 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain Science, Fudan University,…

read more
Start Typing